Cigna GroupCI
Cigna Group Financial Overview 2020–2024
The Cigna Group executed a massive profitability turnaround with a 135% net income surge by Q3 2025, proving its aggressive pivot away from traditional health insurance is paying off. The health giant is actively shedding government plan liabilities to double down on Evernorth, its pharmacy platform that posted 32% adjusted revenue growth in FY2024. This transformation represents a complete restructuring of the company's earnings power. Shareholders' net income initially contracted from $8.46 billion in FY2020 to $3.4 billion in FY2024, despite total revenues climbing to $247.1 billion in FY2024. That temporary bottom-line compression was driven by a $2.7 billion impairment on VillageMD and rising medical costs, forcing a strategic reset.
To unlock capital, Cigna divested its Medicare Advantage portfolio for $4.2 billion in early FY2025, insulating the company from a medical care ratio that had spiked by 190 basis points in FY2024. Management simultaneously funneled operational cash flows into relentless equity repurchases. Outstanding shares shrank from 0.35 billion at the close of FY2020 to 0.27 billion by the end of FY2024, effectively consolidating ownership just as the core business rebounded. Valued against an earnings base of $12.12 EPS at the close of FY2024, the restructured portfolio has successfully transitioned the company into a leaner, pharmacy-led enterprise.
Recent Developments (Q2 and Q3 2025)
Cigna Group sustained its momentum through the first nine months of 2025, driven by Evernorth's expansion. Total revenues climbed 12% year-over-year to reach $202.4 billion by the end of Q3 2025. This growth was concentrated in Pharmacy revenues, which surged 17%, while the Cigna Healthcare segment contracted 9%. Management reaffirmed its 2025 adjusted earnings guidance of at least $29.60 per share. The company also optimized its capital structure by issuing $4.5 billion in senior notes to retire $2.0 billion in term loan debt.
Bulls argue that flat year-over-year Selling, General, and Administrative expenses demonstrate strict cost discipline amidst pharmacy scaling. Conversely, bears caution that the sustained revenue drop in healthcare highlights top-line headwinds for the legacy insurance arm. Trading at 20.4x earnings as of the Q3 2025 report on October 29, 2025, the stock appears richly valued given the ongoing operational transition.
What to watch: progress on Evernorth's pre-tax adjusted income margins; board committee transitions regarding artificial intelligence oversight effective January 1, 2026.
Rev
$247.12B
FY2024
NI
$3.43B
FY2024
EPS
$12.25
FY2024
OCF
$10.36B
FY2024
Year-over-year comparison from 10-K annual reports
Data from SEC Company Facts
Recent SEC Filings
Cigna Group 8-K Report, Financial Results (Feb 5, 2026)
The Cigna Group (CI) filed an 8-K on February 5, 2026, to announce its financial results for the three months and full year ended December 31, 2025. The details of these results are provided in a press release furnished as Exhibit 99.1 to the filing. This report serves to officially inform the market about the company's performance as of the end of the 2025 fiscal year. Investors should refer to the furnished press release (Exhibit 99.1) for specific financial metrics, including revenue, earnings per share, and any forward-looking guidance. The 8-K itself primarily serves as a notification mechanism for the release of this important financial information and does not contain the detailed financial statements or operational analysis within its text, directing readers to the exhibit for those crucial details.
Cigna Group 8-K Report, Corporate Update (Nov 18, 2025)
The Cigna Group (CI) has filed an 8-K detailing significant changes to its Board of Directors' committee structure, effective January 1, 2026. These adjustments are a proactive response to the evolving health services industry and aim to enhance corporate governance and strategic alignment. The primary changes involve the dissolution of the standalone Compliance Committee, with its responsibilities being absorbed by other committees and the full Board. This reflects a strategic streamlining following the divestiture of certain Medicare businesses earlier in 2025. Investors should note that while compliance oversight remains a priority, its structure is being reorganized for greater efficiency and integration with broader company strategy. The Audit Committee will be renamed the "Audit and Compliance Committee" to incorporate oversight of enterprise compliance matters. The Corporate Governance Committee will gain responsibility for the company's ethics program and public clinical reporting. Crucially, oversight of clinical compliance, including patient experience, will now fall under the purview of the full Board, emphasizing its strategic importance. Furthermore, technology oversight, encompassing areas like AI, cybersecurity, and business continuity, will be consolidated under the Finance Committee, which will be renamed the "Finance and Technology Committee." These changes signal a commitment to adapting governance to the company's current strategic focus and operational landscape.
Cigna Group 8-K Report, Financial Results (Oct 30, 2025)
The Cigna Group (CI) has filed a Form 8-K on October 29, 2025, primarily to announce its financial results for the three months ended September 30, 2025. The detailed financial performance is provided in a press release, furnished as Exhibit 99.1, which investors should review for a comprehensive understanding of the company's operational and financial condition during the third quarter of 2025. This filing does not contain new material agreements or executive changes, but serves as the official channel for disseminating the latest quarterly earnings information.
Cigna Group 8-K Report, Executive Changes (Oct 20, 2025)
The Cigna Group (CI) has filed an 8-K report indicating the upcoming retirement of a long-standing Board member, Retired Major General Elder Granger, M.D. The retirement is scheduled to take effect on December 31, 2025. This departure aligns with the company's established retirement age policy and is explicitly stated to be free of any disagreements between Dr. Granger and the Company. While the departure of a board member can sometimes signal underlying issues, the disclosed reasons here suggest a planned and orderly transition, which is a positive indicator for corporate governance and stability.
Cigna Group 8-K Report, Material Agreement (Sep 4, 2025)
The Cigna Group (CI) has announced the successful completion of a significant debt offering totaling $4.5 billion. The offering comprised four tranches of senior notes with varying maturities and interest rates, ranging from 4.500% for the 2030 Notes to 6.000% for the 2056 Notes. This issuance is primarily aimed at repaying $2.0 billion of outstanding loans, which were used to fund a strategic investment in another company. The remaining proceeds will be allocated towards general corporate purposes, including potential future investments and debt repayment.
View all 8-K filings →